2-Bromo-LSD, also known as BOL-148 or as bromolysergide, is a derivative of lysergic acid invented by Albert Hofmann, as part of the original research from which the closely related compound LSD was also derived.

Mar 28, 2023 · Hallucinations limit widespread therapeutic use of psychedelics as rapidly acting antidepressants. Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at s …

2-Bromo-LSD is a serotonin 5-HT 2A receptor antagonist. 3 The compound blocks the effects of LSD, 4 but has no psychological effects on its own. 5 A 1959 human study reported that some tolerance does develop to 2-Bromo-LSD, and prolonged administration does not cause a significant resistance to the effects of LSD. 6

Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminer-gic GPCRs, including 5-HT2A, and does not induce the head-twitch response (HTR) in mice, supporting its classification as a non-hall...

BetterLife Pharma’s lead product, 2-Bromo-LSD (BETR-001), is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that mimics the projected therapeutic properties of LSD without causing its undesirable side effects such as hallucinations.

Mar 21, 2024 · 2-Bromo-LSD (2-Bromolysergic acid diethylamide) — sometimes called BOL-148 — is believed to block the effects of LSD. It binds to the same receptors but does not exert any psychedelic activity. This compound was one of many ergotamine derivatives invented by Albert Hofmann and his team in the late 1950s.

Bromolysergide | C20H24BrN3O | CID 10171 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.

Sep 1, 2023 · BetterLife Pharma’s lead candidate, BETR-001 (2-bromo-LSD), is a non-hallucinogenic derivative of LSD that mimics the projected therapeutic properties of LSD without negative side effects such as heart damage.

Here we profiled the non-hallucinogenic lysergic acid diethylamide (LSD) analog 2-bromo-LSD (2-Br-LSD) at more than 33 aminergic G protein-coupled receptors (GPCRs). 2-Br-LSD shows partial agonism at several aminergic GPCRs, including 5-HT2A, and does not induce the head-twitch response (HTR) in mice, supporting its classification as a non-hallu...

Nov 18, 2021 · It has been a big week for BetterLife Pharma Inc (CSE:BETR, OTCQB:BETRF), as the life sciences company revealed that they now have received the behavioural animal pharmacology data in relations to their leading candidate 2-bromo-LSD (TD-0148A).